Objective To construct the prokaryotic expression vector pET-32a(+)-C2orf69 and induce the expression of recombinant proteins in vitro. Then the possible effects of recombinant protein on cell proliferation was observed and rabbit-anti-C2orf69 protein polyclonal antibodies was obtained.
Methods Gene fragment of C2orf69 was amplified by PCR and then prokaryotic expression plasmid pET-32a(+)-C2orf69 was constructed. Recombinant protein C2orf69 expression was identified by SDS-PAGE and Western blot. The white-ear rabbits were immunized with purified recombinant protein C2orf69, and the potency and specificity of polyclonal antibody were evaluated by enzyme-linked immunosorbent assay (ELISA) and Western blot. Also, different liver cells were incubated with recombinant protein C2orf69 in vitro.
Results C2orf69 gene fragment was successfully amplified, results of gene sequencing were consistent with the sequence in GenBank. Recombinant protein of C2orf69 was successfully induced and expressed. The polyclonal antibody titer was up to 1︰1 280 000 through enzyme-linked immunosorbent assay. Results of cell proliferation showed that the recombinant protein could inhibit the proliferation of different liver cells.
Conclusions The recombinant protein C2orf69 could inhibit the proliferation of different liver cells, and we speculated that it may be a widely roled inhibitor of hepatocyte proliferation. Our experiment showed that the proliferation inhibition of cells may be realized by G1 phase extending and S phase shortening.
1. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis 2007; 16(4):403-406.
2. Aalaei-Andabili SH, Alavian SM. Regulatory T cells are the most important determinant factor of hepatitis B infection prognosis: a systematic review and meta-analysis. Vaccine 2012; 30(38):5595-5602.
3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142(6):1264-1273.
4. Tang R, Kong F, Hu L, You H, Zhang P, Du W, et al. Role of hepatitis B virus X protein in regulating LIM and SH3 protein 1 (LASP-1) expression to mediate proliferation and migration of hepatoma cells. Virol J 2012; 9:163.
5. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006; 1:23-61.
6. Li GL, Wei HS, Song SJ. The effect of angiotensin II on the gene expression of hepatic stellate cells. Zhonghua Gan Zhang Bing Za Zhi (Chin) 2006; 14(12):914-919.
7. Feng JY, Shao JG. The current state on hepatitis B virus in specific cellular immune. Nantong Da Xue Xue Bao: Yi Xue Ban (Chin) 2012; 32(1):54-57.
8. Yong XZ, Li YF. Current status and advance of CD8+ CTL in occurrence of hepatitis B. Shi Jie Hua Ren Xiao Hua Za Zhi (Chin) 2009; 17(4): 384-388.
9. Hui IC, Tung EK, Sze KM, Ching YP, Ng IO. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signaling in hepatocellular carcinoma. Liver Int 2010; 30(1):65-75.
10. Li S, Liang Y, Wu M, Wang X, Fu H, Chen Y, et al. The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells. Cancer Cell Int 2013; 13(1):30.
11. Choi HJ, Fukui M, Zhu BT. Role of cyclin B1/Cdc2 upregulation in the development of mitotic prometaphase arrest in human breast cancer cells treated with nocodazole. PLoS One 2011; 6(8):e24312.
12. Motokura T, Bloom T, Kim HG, Jüppner H, Ruderman JV, Kronenberg HM, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991; 350(6318):512-515.
13. Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007; 45(5):1298-1305.
14. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17(1):9-26.
15. Fidalgo da Silva E, Ansari SB, Maimaiti J, Barnes EA, Kong-Beltran M, Donoghue DJ, et al. The tumor suppressor tuberin regulates mitotic onset through the cellular localization of cyclin B1. Cell Cycle 2011; 10(18):3129-3139.
16. Yang L, Inokuchi S, Roh YS, Song J, Loomba R, Park EJ, et al. Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. Gastroenterology 2013; 144(5):1042-1054.
17. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134(6):1655-1669.
18. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88(1):125-172.
19. Amann T, Bataille F, Spruss T, Mühlbauer M, Gäbele E, Schölmerich J, et al. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 2009; 100(4):646-653.
20. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2011; 21(1):35-43.
21. Zhao W, Zhang L, Yin Z, Su W, Ren G, Zhou C, et al. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int J Cancer 2011; 129(11):2651-2661.
22. Seki N, Toh U, Kawaguchi K, Ninomiya M, Koketsu M, Watanabe K, et al. Tricin inhibits proliferation of human hepatic stellate cells in vitro by blocking tyrosine phosphorylation of PDGF receptor and its signaling pathways. J Cell Biochem 2012; 113(7):2346-2355.